A carregar...
Bendamustine in the treatment of B-cell non-Hodgkin lymphoma
Bendamustine is a uniquely structuredalkylating agent that lacks cross-resistance with other alkylators. This agent has a high degreeof activity against a variety of tumor cell lines.Based on clinical data from randomized phase III trials, bendamustine, with or without rituximab, hasbeen shown to be...
Na minha lista:
Main Authors: | , |
---|---|
Formato: | Artigo |
Idioma: | Russo |
Publicado em: |
IP Habib O.N.
2018-12-01
|
Colecção: | Современная онкология |
Assuntos: | |
Acesso em linha: | https://modernonco.orscience.ru/1815-1434/article/viewFile/29575/pdf |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|